These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

865 related articles for article (PubMed ID: 17169640)

  • 21. Epidemiology, risk factors and comorbidity for urinary tract infections caused by extended-spectrum beta-lactamase (ESBL)-producing enterobacteria.
    Briongos-Figuero LS; Gómez-Traveso T; Bachiller-Luque P; Domínguez-Gil González M; Gómez-Nieto A; Palacios-Martín T; González-Sagrado M; Dueñas-Laita A; Pérez-Castrillón JL
    Int J Clin Pract; 2012 Sep; 66(9):891-6. PubMed ID: 22897466
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incidence of acute prostatitis caused by extended-spectrum beta-lactamase-producing Escherichia coli after transrectal prostate biopsy.
    Ozden E; Bostanci Y; Yakupoglu KY; Akdeniz E; Yilmaz AF; Tulek N; Sarikaya S
    Urology; 2009 Jul; 74(1):119-23. PubMed ID: 19464043
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk factors and clinical outcomes of extended spectrum beta-lactamase (ESBL)-producing Escherichia coli septicemia at Srinagarind University Hospital, Thailand.
    Anunnatsiri S; Towiwat P; Chaimanee P
    Southeast Asian J Trop Med Public Health; 2012 Sep; 43(5):1169-77. PubMed ID: 23431823
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections.
    Azap OK; Arslan H; Serefhanoğlu K; Colakoğlu S; Erdoğan H; Timurkaynak F; Senger SS
    Clin Microbiol Infect; 2010 Feb; 16(2):147-51. PubMed ID: 19689464
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome.
    Ortega M; Marco F; Soriano A; Almela M; Martínez JA; Muñoz A; Mensa J
    J Antimicrob Chemother; 2009 Mar; 63(3):568-74. PubMed ID: 19126669
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of risk factors for the acquisition of bloodstream infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in the intensive care unit; antibiotic management and clinical outcome.
    Cordery RJ; Roberts CH; Cooper SJ; Bellinghan G; Shetty N
    J Hosp Infect; 2008 Feb; 68(2):108-15. PubMed ID: 18063198
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular epidemiology of Escherichia coli producing extended-spectrum {beta}-lactamases in Lugo (Spain): dissemination of clone O25b:H4-ST131 producing CTX-M-15.
    Blanco M; Alonso MP; Nicolas-Chanoine MH; Dahbi G; Mora A; Blanco JE; López C; Cortés P; Llagostera M; Leflon-Guibout V; Puentes B; Mamani R; Herrera A; Coira MA; García-Garrote F; Pita JM; Blanco J
    J Antimicrob Chemother; 2009 Jun; 63(6):1135-41. PubMed ID: 19351692
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk-factors for acquisition of extended-spectrum beta-lactamase-producing Escherichia coli among hospitalised patients.
    Peña C; Gudiol C; Tubau F; Saballs M; Pujol M; Dominguez MA; Calatayud L; Ariza J; Gudiol F
    Clin Microbiol Infect; 2006 Mar; 12(3):279-84. PubMed ID: 16451416
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and molecular epidemiology of extended-spectrum beta-lactamase-producing Escherichia coli as a cause of nosocomial infection or colonization: implications for control.
    Rodríguez-Baño J; Navarro MD; Romero L; Muniain MA; Perea EJ; Pérez-Cano R; Hernández JR; Pascual A
    Clin Infect Dis; 2006 Jan; 42(1):37-45. PubMed ID: 16323089
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activity of ertapenem and other antimicrobials against ESBL-producing enterobacteria isolated from urine in patients from Madrid.
    Tamayo J; Orden B; Cacho J; Cuadros J; Gomez-Garces JL; Alos JI
    Rev Esp Quimioter; 2007 Sep; 20(3):334-8. PubMed ID: 18080031
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors and treatment outcomes of community-onset bacteraemia caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    Kang CI; Song JH; Chung DR; Peck KR; Ko KS; Yeom JS; Ki HK; Son JS; Lee SS; Kim YS; Jung SI; Kim SW; Chang HH; Ryu SY; Kwon KT; Lee H; Moon C; Shin SY;
    Int J Antimicrob Agents; 2010 Sep; 36(3):284-7. PubMed ID: 20580534
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Community-onset extended-spectrum beta-lactamase (ESBL) producing Escherichia coli: importance of international travel.
    Laupland KB; Church DL; Vidakovich J; Mucenski M; Pitout JD
    J Infect; 2008 Dec; 57(6):441-8. PubMed ID: 18990451
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Community emergence of CTX-M type extended-spectrum beta-lactamases among urinary Escherichia coli from women.
    Ho PL; Poon WW; Loke SL; Leung MS; Chow KH; Wong RC; Yip KS; Lai EL; Tsang KW;
    J Antimicrob Chemother; 2007 Jul; 60(1):140-4. PubMed ID: 17496058
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nursing homes as a reservoir of extended-spectrum beta-lactamase (ESBL)-producing ciprofloxacin-resistant Escherichia coli.
    Rooney PJ; O'Leary MC; Loughrey AC; McCalmont M; Smyth B; Donaghy P; Badri M; Woodford N; Karisik E; Livermore DM
    J Antimicrob Chemother; 2009 Sep; 64(3):635-41. PubMed ID: 19549667
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and economic impact of urinary tract infections caused by ESBL-producing Escherichia coli requiring hospitalization: A matched cohort study.
    Esteve-Palau E; Solande G; Sánchez F; Sorlí L; Montero M; Güerri R; Villar J; Grau S; Horcajada JP
    J Infect; 2015 Dec; 71(6):667-74. PubMed ID: 26380898
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clonal dissemination of highly virulent extended-spectrum beta-lactamase-producing Escherichia coli strains isolated from the urine of non-hospitalised patients in Zagreb region.
    Vranes J; Marijan T; Bedenic B; Mlinaric-Dzepina A; Katic S; Kalenic S
    Int J Antimicrob Agents; 2008 Feb; 31 Suppl 1():S19-24. PubMed ID: 17936594
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical characteristics of urosepsis caused by extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumonia and their emergence in the community.
    Lee JC; Lee NY; Lee HC; Huang WH; Tsui KC; Chang CM; Lee CC; Chen PL; Wu CJ; Hsueh PR; Ko WC
    J Microbiol Immunol Infect; 2012 Apr; 45(2):127-33. PubMed ID: 22041167
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Increasing prevalence of fosfomycin resistance in extended-spectrum-beta-lactamase-producing Escherichia coli urinary isolates (2005-2009-2011)].
    Rodríguez-Avial C; Rodríguez-Avial I; Hernández E; Picazo JJ
    Rev Esp Quimioter; 2013 Mar; 26(1):43-6. PubMed ID: 23546462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies.
    Trecarichi EM; Tumbarello M; Spanu T; Caira M; Fianchi L; Chiusolo P; Fadda G; Leone G; Cauda R; Pagano L
    J Infect; 2009 Apr; 58(4):299-307. PubMed ID: 19272650
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Antibiotic resistance rates of extended spectrum beta-lactamase producing Escherichia coli and Klebsiella spp. strains isolated from urinary tract infections in a private hospital].
    Akyar I
    Mikrobiyol Bul; 2008 Oct; 42(4):713-5. PubMed ID: 19149097
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.